Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy.

Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy. Abstract Text:

    xing chenXing Chen,yongli chenYongli Chen,yanyong biYanyong Bi,naikuan fuNaikuan Fu,chunyan shanChunyan Shan,sili wangSili Wang,shahid aslamShahid Aslam,peixian wang wangPeixian Wang Wang,jing xuJing Xu,xing chenXing Chen,yongli chenYongli Chen,yanyong biYanyong Bi,naikuan fuNaikuan Fu,chunyan shanChunyan Shan,sili wangSili Wang,shahid aslamShahid Aslam,peixian wang wangPeixian Wang Wang,jing xuJing Xu,

    INTRODUCTION: Doxorubicin (DOX) is a highly effective chemotherapeutic agent related to dose-dependent cardiomyopathy. Recent evidence suggests that erythropoietin (EPO) can play a protective role in cardiovascular diseases by non-erythropoietic effects. In the present study, we tested the hypothesis that EPO may protect against DOX-induced cardiomyopathy through anti-apoptotic mechanisms both in vitro and in vivo. MATERIALS AND METHODS: Isolated neonatal Wistar rat cardiomyocytes were treated with vehicle, DOX with or without EPO, or EPO. Twenty-four hours later, the cells were used to determine cardiomyocyte apoptosis (TUNEL assay). Cardiomyopathy was induced in Wistar rats by intraperitoneal injections (IP) of DOX (2.5 mg/kg, six times for 2 weeks). EPO (2,500 U/kg, six times for 2 weeks) was administered simultaneously in the DOX+EPO group and the EPO group. Two weeks after the last administration, cardiac function was evaluated by echocardiography and invasive haemodynamic measurements. Rats were then sacrificed for histological and TUNEL analyses, with immunological detection for cardiac Troponin-T (cTnT), alpha-actinin, Bax and Bcl-2. RESULTS: EPO significantly ameliorated DOX-induced apoptosis of cultured cardiomyocytes as demonstrated by TUNEL assay. In the rat model, cardiac function significantly decreased in the DOX group. In contrast, the DOX+EPO group showed considerable improvement in cardiac function, inhibition of cardiomyocyte apoptosis, reduction of fibrosis, as well as up-regulation of Bcl-2 protein expression. CONCLUSIONS: Our results suggest that EPO exerts preventive cardioprotective effects on DOX-induced cardiomyopathy via anti-apoptotic pathways. The up-regulation of Bcl-2 protein expression may contribute to this.

    Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy. Publishing Authors By Initials

    x chenX Chen,y chenY Chen,y biY Bi,n fuN Fu,c shanC Shan,s wangS Wang,s aslamS Aslam,pw wangPW Wang,j xuJ Xu,x chenX Chen,y chenY Chen,y biY Bi,n fuN Fu,c shanC Shan,s wangS Wang,s aslamS Aslam,pw wangPW Wang,j xuJ Xu,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Cardiovascular drugs and therapy / sponsored by th

    VOLUME: 21

    Page Numbers: 367-74

    Journal Abbreviation:

    ISSN: 0920-3206

    DAY: 26

    MONTH: Oct

    YEAR: 2007

    Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 8712220

    Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy.

    AFFILIATION: Department of Cardiology, General Hospital of Tianjin Medical University, Tianjin, China.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Cardiovasc Drugs Ther

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News